comparemela.com

Latest Breaking News On - 2023 san antonio breast cancer symposium - Page 1 : comparemela.com

Sammons Spotlights Approaches Under Exploration for HER2+ Breast Cancer and Brain Metastases

Sarah Sammons, MD, discusses research efforts in breast cancer focused on HER2-directed therapeutic approaches with central nervous system activity.

United statesDana farber cancer instituteSan antonioSarah sammonsMemorial sloan kettering cancer centerMetastatic breast cancer programAntonio breast cancerAntonio breast cancer symposiumPhase 2 her2climb trial nct02614794Phase 3 her2climb 02 trial nct039756472023 san antonio breast cancer symposium

Patient Toxicity and QOL Concerns Must Be Considered in Breast Cancer Treatment Decision-Making

Jane L. Meisel, MD, discusses the importance of prioritizing patients’ toxicity concerns and quality of life in the management of breast cancer.

United statesEmory university school of medicineSan antonioJanel meiselDepartment of gynecologyQuality of lifeDepartment of hematologyLife surveyAntonio breast cancer symposiumMedical oncologyEmory university schoolEstrogen receptor positive her2 negativeBreast cancerTreatment related adverse effectsHealthcare providersTolerability concerns

Addressing Patient-Provider Communication Challenges is Vital for Improved Breast Cancer Care

Jane L. Meisel, MD, highlighted patient-reported gaps in provider communication regarding treatment-related toxicities in metastatic breast cancer.

United statesEmory university school of medicineJanel meiselDepartment of gynecologyDepartment of hematologyQuality of lifeLife surveyAntonio breast cancer symposiumMedical oncologyEmory university schoolEstrogen receptor positive her2 negativeBreast cancerTreatment related adverse effectsHealthcare providersTolerability concernsShared decision making

SABCS 2023 Findings Build on Positive Momentum in HER2+ Breast Cancer

Expert oncologists in the field of breast cancer review data in HER2-positive early-stage and metastatic breast cancer.

San antonioUnited statesHeather mcarthurPriyanka sharmaClaudine isaacsJoyce oshaughnessyOnclive peer exchangeStudy groupAntonio breast cancer symposiumEarly stage breastEarly stage breast cancerExploratory analysisSecond line treatmentMetastatic breastMetastatic breast cancerThird line

Disitamab Vedotin Combos Show Efficacy in HER2+ and HER2-Low Breast Cancers

Disitamab vedotin alone and paired with immune checkpoint inhibitors, TKIs, or other antiangiogenic compounds showcased consistent efficacy and tolerability in patients with HER2-positive or HER2-low locally advanced or metastatic breast cancer.

San antonioUnited statesFirst affiliated hospital of nanjing medical universityAntonio breast cancerFirst affiliated hospitalNanjing medical universityDisitamab vedotinHer2 positive or low locally advanced metastatic breast cancerImmune checkpoint inhibitors2023 san antonio breast cancer symposiumBreast cancer

vimarsana © 2020. All Rights Reserved.